BOTANIX PHARMACEUTICALS LTD — Director's Dealing 2019

Dec 9, 2019

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited

ABN 70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Michael Thurn
Date of last notice	23 July 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.	Dr Thurn is the trustee of the Thurn Family Trust
Date of change	10 December 2019
No. of securities held prior tochangeMichael Joseph ThurnMichael Joseph Thurn	200,000 Ordinary Shares5,000,000 Unlisted Options expiring on 18/07/2023 exercisable at$0.2512,096,608 Ordinary Shares1,000,000 Unlisted Options expiring on 05/12/2019 exercisable at$0.082,882,837 Unlisted Options expiring on 08/05/2020 exercisable at$0.072,000,000 Unlisted Options expiring on 05/12/2021 exercisable at$0.106
Class	Ordinary SharesUnlisted Options
Number acquired	249,889 Ordinary Shares

Number disposed	1,000,000 Unlisted Options exercised utilising cashless exercisefacility
Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation	Nil
No. of securities held after changeMichael Joseph ThurnMichael Joseph Thurn	200,000 Ordinary Shares5,000,000 Unlisted Options expiring on 18/07/2023 exercisable at$0.2512,346,497 Ordinary Shares2,882,837 Unlisted Options expiring on 08/05/2020 exercisable at$0.072,000,000 Unlisted Options expiring on 05/12/2021 exercisable at$0.106
Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation inbuy-back	Exercise of Unlisted Options utilising cashless exercise facilityunder the Company’s Employee Securities Incentive Plan

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A

If prior written clearance was provided, on what date was this N/A provided?